New Class of Molecules Shows Promise Against ER-Positive Breast Cancer
Overview: Why this development matters
Tens of millions of women worldwide are diagnosed with breast cancer, and more than 70% of these tumors are classified as estrogen receptor–positive (ER-positive). ER-positive cancers grow in response to estrogen signaling, so therapies that interrupt that pathway form a cornerstone of clinical management. When tumors become resistant to first-line endocrine therapies or spread beyond the breast, doctors often rely on treatments that directly target and eliminate estrogen receptors on cancer cells. The new class of small molecules reported by a United States research team represents a potentially significant expansion of that therapeutic toolkit.
Current treatments and their limitations
Endocrine therapies commonly used for ER-positive disease aim to reduce estrogen production or block estrogen signaling. Selective estrogen receptor degraders (SERDs) represent a category of small molecules designed to bind to estrogen receptors and promote their breakdown, thereby shutting down the receptor-driven growth signal. In clinical practice, SERDs are frequently reserved as a later-line option for patients whose tumors no longer respond to other endocrine strategies or for those with metastatic disease.
At present, only one SERD has regulatory approval from the U.S. Food and Drug Administration for clinical use. That approved agent requires administration by injection, a delivery method that can be painful and less convenient for patients. The scarcity of approved SERDs and the drawbacks of current delivery options have driven ongoing research to discover orally bioavailable, better tolerated, and more broadly effective small molecules that degrade estrogen receptors.
The newly developed molecules: structure and modular design
Researchers in the United States have developed a new class of SERD molecules characterized by a distinctive chemical structure that interferes with estrogen receptor function. The team’s approach emphasizes a modular design: the core scaffold of the molecules can be adapted to produce multiple related variants. This modularity enabled the researchers to synthesize a series of candidate compounds efficiently and systematically evaluate how structural changes affected biological activity.
The unique structural features identified by the investigators are notable because they were only recently recognized as effective at disrupting estrogen receptor stability. By leveraging that insight, the researchers expanded the range of molecular architectures available for designing SERDs, thereby widening the possibilities for future drug development.
Laboratory testing: effects on estrogen receptors and cancer cell growth
To assess the biological activity of their new compounds, the research team tested 15 representative molecules in laboratory experiments using breast cancer cells. These in vitro studies examined two key outcomes: whether the compounds caused degradation or damage of estrogen receptors within cancer cells, and whether treatment reduced the cells’ ability to proliferate.
Experimental results demonstrated that the candidate molecules indeed targeted the estrogen receptors and led to receptor damage or degradation. Correspondingly, breast cancer cell growth slowed in the presence of these novel SERD candidates. These findings establish proof of concept that the chemical series can achieve the intended molecular effect—direct disruption of ER function—and exert an antiproliferative impact on ER-positive breast cancer cells in vitro.
Implications for treatment options and next steps
The discovery of this new SERD class substantially increases the number of molecular strategies that can be pursued for ER-positive breast cancer. By expanding the diversity of molecules capable of degrading estrogen receptors, the research opens pathways to developing agents that may overcome limitations of existing therapies—such as the need for injectable administration—or address resistance mechanisms that diminish current drug effectiveness.
According to the research team, the immediate next phase is to select a subset of the most promising molecules from the initial series and evaluate them in animal studies. Mouse models will be used to investigate pharmacokinetics, tolerability, systemic activity, and antitumor efficacy in vivo. Those preclinical data will be essential to determine which candidates merit further medicinal chemistry optimization and potential advancement toward formal drug development programs.
Research provenance and citation
This work was conducted by a U.S.-based research team and reported in medichelpline. The study that describes the new class of selective estrogen receptor degraders is cited as: Wang L, Guillen VS, Sharma N et al. New class of selective estrogen receptor degraders (SERDs): Expanding the toolbox of PROTAC degrons. 2018. medichelpline. The experimental results summarized here are limited to the data reported by the investigators—laboratory-based receptor degradation and growth inhibition—and the authors’ stated intention to progress selected molecules into mouse studies.
This development represents an encouraging step in preclinical SERD research, offering new molecular frameworks for targeting ER-positive breast cancer. Continued, rigorous preclinical evaluation will determine whether these early findings can be translated into clinically useful therapeutics that expand treatment choices for patients with endocrine-resistant or metastatic ER-positive disease.